Received: 25.04.2025 Accepted: 29.08.2025 Published online: 31.10.2025
УДК: 616.5-002.525-085.357.4
DOI: 10.53511/PHARMKAZ.2025.5.1
RITUXIMAB IN THE TREATMENT OF PEMPHIGUS VULGARIS: A CLINICAL REVIEW
Ospanova S.A.¹, Sukhanberdiyeva Z.M.¹, Arinova A.N.¹, Idrissova A.S.¹
¹ Kazakh Science Dermatology and Infectious Diseases MH of RK, Almaty, Kazakhstan
Introduction. Pemphigus vulgaris (PV) is a severe autoimmune disease affecting the skin and mucous membranes. In recent years, rituximab, a monoclonal anti-CD20 antibody, has emerged as a first-line treatment for moderate-to-severe cases.
Materials and Methods. This review analyzes current data on rituximab use in adults and children, including administration protocols, relapse management, safety monitoring, and strategies to reduce corticosteroid and immunosuppressant doses.
Results. Rituximab has demonstrated high efficacy and steroid-sparing effects in adults. In children, despite off-label use, it is effective in severe cases. Repeat and prophylactic courses help control relapses. The drug is generally well tolerated with proper premedication and monitoring.
Discussion. Rituximab is now recognized as an effective and safe first-line option in PV, allowing for long-term disease control and reduction of treatment burden.
Conclusion. Rituximab plays a central role in modern PV therapy, improving patient outcomes and quality of life. Further studies are needed to refine pediatric treatment protocols.
Keywords: pemphigus vulgaris, rituximab, CD20, autoimmune disease, clinical guidelines,immunosuppression.
